J E Karp

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi request reprint Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
    J E Karp
    University of Maryland Greenebaum Cancer Center, 22 S Greene St, Baltimore, MD 21201, USA
    Blood 97:3361-9. 2001
  2. ncbi request reprint Current status of clinical trials of farnesyltransferase inhibitors
    J E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Curr Opin Oncol 13:470-6. 2001
  3. pmc Induction of acute lymphocytic leukemia differentiation by maintenance therapy
    T L Lin
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Leukemia 21:1915-20. 2007
  4. ncbi request reprint Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
    J E Karp
    Department of Medicine, Greenebaum Cancer Center, University of Maryland School of Medicine, 22 S. Greene St, Baltimore, MD 21201, USA
    Semin Hematol 38:16-23. 2001
  5. ncbi request reprint New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy
    B D Smith
    Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Biol Regul Homeost Agents 19:23-32. 2005
  6. pmc A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
  7. ncbi request reprint Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
    D D Ross
    University of Maryland Greenebaum Cancer Center the Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Blood 96:365-8. 2000
  8. ncbi request reprint Farnesyltransferase inhibitors (FTIs) in myeloid malignancies
    J E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 289, Baltimore, Maryland, USA
    Ann Hematol 83:S87-8. 2004
  9. pmc Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
    Mark Levis
    Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 108:3477-83. 2006
  10. pmc Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Blood 109:2781-90. 2007

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
    J E Karp
    University of Maryland Greenebaum Cancer Center, 22 S Greene St, Baltimore, MD 21201, USA
    Blood 97:3361-9. 2001
    ..The results of this first clinical trial of a signal transduction inhibitor in patients with acute leukemias suggest that inhibitors of FT may have important clinical antileukemic activity. (Blood. 2001;97:3361-3369)..
  2. ncbi request reprint Current status of clinical trials of farnesyltransferase inhibitors
    J E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA
    Curr Opin Oncol 13:470-6. 2001
    ..Preclinical studies of farnesyltransferase inhibitor resistance and clinical trials of farnesyltransferase inhibitors in combination with other agents currently are in progress...
  3. pmc Induction of acute lymphocytic leukemia differentiation by maintenance therapy
    T L Lin
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Leukemia 21:1915-20. 2007
    ..These data suggest that induction of leukemia progenitor differentiation plays an important role in the mechanism of action of maintenance therapy in ALL...
  4. ncbi request reprint Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
    J E Karp
    Department of Medicine, Greenebaum Cancer Center, University of Maryland School of Medicine, 22 S. Greene St, Baltimore, MD 21201, USA
    Semin Hematol 38:16-23. 2001
    ..The biologic and antitumor activity and favorable tolerability of R115777 support further clinical evaluation alone and in combination therapy in hematologic malignancies...
  5. ncbi request reprint New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy
    B D Smith
    Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    J Biol Regul Homeost Agents 19:23-32. 2005
    ....
  6. pmc A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
    K W Pratz
    Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 24:1437-44. 2010
    ..Although sorafenib showed only modest clinical activity as a single agent in this heavily treated population, robust inhibition of FLT3 and ERK suggests that there may be a potential important role in combination therapies...
  7. ncbi request reprint Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
    D D Ross
    University of Maryland Greenebaum Cancer Center the Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Blood 96:365-8. 2000
    ..High expression of BCRP mRNA is sufficiently frequent in AML to warrant more extensive investigations to determine the relation of disease subtype and treatment outcome to BCRP expression and function...
  8. ncbi request reprint Farnesyltransferase inhibitors (FTIs) in myeloid malignancies
    J E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 289, Baltimore, Maryland, USA
    Ann Hematol 83:S87-8. 2004
    ..It is anticipated that these studies will serve to define the optimal roles of FTIs in patients with hematologic malignancies and provide insight into effective methods by which to combine FTIs with other agents...
  9. pmc Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
    Mark Levis
    Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 108:3477-83. 2006
    ..Additionally, our results suggest that nonselectivity may constitute an important component of the cytotoxic effect of FLT3 inhibitors in FLT3-mutant AML...
  10. pmc Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Blood 109:2781-90. 2007
    ..No responses by classical criteria were seen. Our results show that MS-275 effectively inhibits HDAC in vivo in patients with advanced myeloid leukemias and should be further tested, preferably in patients with less-advanced disease...
  11. ncbi request reprint Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  12. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ....
  13. ncbi request reprint Developmental clinical trials: building one step at a time
    Judith E Karp
    Leuk Res 30:765-6. 2006
  14. ncbi request reprint Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry
    Eun Joo Chung
    Medical Oncology Clinical Research Unit, Bethesda, MD 20892, USA
    Ann Clin Lab Sci 35:397-406. 2005
    ..The technique described has significant advantages for the PD assessment of HDAC inhibitors as monotherapy and as a component of combination therapy trials...
  15. ncbi request reprint Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
    Milin R Acharya
    Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA
    Invest New Drugs 24:367-75. 2006
    ..To evaluate elimination pathways of the histone deacetylase inhibitor MS-275 in vitro and screen for relationships between demographic factors that may affect its pharmacokinetics in vivo...
  16. ncbi request reprint Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Leuk Res 31:1165-73. 2007
    ..2-5.5 microM) was above levels required to achieve in vitro/in vivo leukemia growth inhibition. Based on these data, we conclude that Triapine warrants further investigation in hematologic malignancies...
  17. ncbi request reprint Ribonucleotide reductase: an old target with new potential
    B Douglas Smith
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21210, USA
    Leuk Res 27:1075-6. 2003
  18. ncbi request reprint Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
    Joya Chandra
    Division of Oncology Research, Guggenheim 1301, Mayo Clinic, 200 First St, SW, Rochester, MN 55901, USA
    Blood 102:4512-9. 2003
    ....
  19. ncbi request reprint Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization
    Xue Wei Meng
    Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 282:29831-46. 2007
    ..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity...
  20. ncbi request reprint Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias
    Jeffrey E Lancet
    University of Rochester, James P Wilmot Cancer Center, Rochester, NY, USA
    Semin Hematol 39:31-5. 2002
    ..These results suggest that Zarnestra should be studied further in patients with myeloid leukemia...
  21. ncbi request reprint Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin
    Eun Joo Chung
    Medical Oncology Clinical Research Unit and Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:982-90. 2002
    ..Fas-mediated apoptosis was potentiated by inhibition of beta-catenin nuclear signaling. The data suggest that beta-catenin can play a significant role in promoting leukemic cell proliferation, adhesion, and survival...
  22. doi request reprint The long road to a cure for acute myelocytic leukemia: from intensity to specificity
    William P Vaughan
    University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    J Clin Oncol 26:3475-7. 2008
  23. pmc Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
    Judith E Karp
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 14:3077-82. 2008
    ..Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR...
  24. ncbi request reprint A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
    ..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...
  25. ncbi request reprint Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231, USA
    Cancer Invest 25:484-94. 2007
    ..Clinical trials and correlative laboratory studies in progress and under development will define the optimal roles of FTIs in cancer patients...
  26. pmc A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Blood 110:1762-9. 2007
    ..This clinical trial is registered with the National Cancer Institute's PDQ at www.clinicaltrials.gov as no. JHOC-J0561...
  27. pmc A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
    Judith E Karp
    Leukemia Program, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 32:71-7. 2008
    ..Drug-related toxicities included fever and metabolic acidosis. Triapine 105 mg/m(2) followed by fludarabine 30 mg/m2 daily x 5 is active in refractory myeloid malignancies and warrants continuing study for patients with aggressive MPD...
  28. ncbi request reprint Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
    ..We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML...
  29. ncbi request reprint Exploiting oxidative damage to overcome resistance
    Judith E Karp
    Leuk Res 30:1213-4. 2006
  30. ncbi request reprint Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies
    Judith E Karp
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Division of Hematologic Malignancies, The Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Future Oncol 1:719-31. 2005
    ..The full development of FTIs for the therapy of hematologic malignancies will require the design and testing of rational combinations of cytotoxic, biologic and immunomodulatory agents in the laboratory and the clinic...
  31. ncbi request reprint Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 2120, USA
    Clin Cancer Res 9:307-15. 2003
    ..trigger apoptosis in fresh acute leukemia; and (b). recruit surviving leukemic cells to a proliferative state, thereby priming such cells for the S-phase-related cytotoxicity of 1-beta-D-arabinofuranosylcytosine (ara-C)...
  32. ncbi request reprint SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:795-801. 2003
    ..Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS...
  33. ncbi request reprint Farnesyl transferase inhibitors in myeloid malignancies
    Jeffrey E Lancet
    University of Rochester, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Blood Rev 17:123-9. 2003
    ....
  34. ncbi request reprint Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
    Jeffrey E Lancet
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    Blood 102:3880-9. 2003
    ..It is anticipated that these studies will serve to define the optimal roles of FTIs in patients with hematologic malignancies and provide insight into effective methods by which to combine FTIs with other agents...
  35. ncbi request reprint Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients
    Takeo Nakanishi
    Department of Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Cancer Res 9:3320-8. 2003
    ..In vitro cell viability and apoptosis were examined after 24 h exposure to flavopiridol...
  36. ncbi request reprint Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
    Xue Wei Meng
    Division of Oncology Research, Guggenheim 1342C, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 278:47326-39. 2003
    ..Collectively, these results identify the MAPK pathway as a potential therapeutic target in ALL and delineate a mechanism by which MEK inhibition triggers apoptosis in ALL cells...
  37. ncbi request reprint Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 10:3577-85. 2004
    ..We conducted a Phase II clinical trial of bevacizumab administered after chemotherapy to adults with refractory or relapsed AML, using a timed sequential therapy (TST) approach...
  38. ncbi request reprint Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005
    ..However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL...
  39. ncbi request reprint Farnesyl transferase inhibitors in myeloid disorders
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Oncology (Williston Park) 19:1043-9; discussion 1049-50, 1053-4. 2005
    ....
  40. ncbi request reprint Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia
    Scott H Kaufmann
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin Cancer Res 11:6641-9. 2005
    ..To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias...
  41. ncbi request reprint New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation
    Ting Bao
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 3:287-96, 302. 2005
    ..This review will focus on several exciting components of these pathways and the agents targeting these pathways that are entering clinical trials...
  42. ncbi request reprint A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
    Kenneth S Bauer
    Greenebaum Cancer Center, University of Maryland School of Pharmacy, Allied Health Building Suite 540, 100 Penn Street, Baltimore, MD 21201, USA
    Leuk Res 29:263-71. 2005
    ..This combination including PSC-833 was well tolerated. Although a pharmacokinetic interaction might have been expected, PSC-833 did not significantly alter the disposition of idarubicin...
  43. ncbi request reprint Farnesyl transferase inhibition in hematologic malignancies
    Judith E Karp
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Harry and Jeanette Weinberg Building, Suite 1100, 401 North Broadway, Baltimore, MD 21231, USA
    J Natl Compr Canc Netw 3:S37-40. 2005
  44. ncbi request reprint Overcoming drug resistance: targeting more than one site
    Judith E Karp
    Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA
    Leuk Res 26:107-9. 2002